Clinical Trial

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 38 -> 42 locations 2026-06-05
Trial Details
NCT Number NCT07215559
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight, Diabetes Mellitus, Type 2
Enrollment 200 participants
Start Date 2025-10-16
Primary Completion 2027-03 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-17